Key Highlights

  • A Nasdaq Hearings Panel granted continued listing in late January 2026.
  • The company regained Nasdaq Capital Market compliance in May 2026.
  • It completed the first phase of GLASO industrialisation in April.
  • The next earnings date is estimated for October 23, 2026.

Moolec Science SA (NASDAQ:MLEC) is a Cayman Islands-domiciled, science-based ingredient company with a market capitalisation of about $4.6 million on roughly 2.08 million shares. It develops products for food, pet food, animal feed and dietary supplements using molecular farming and precision fermentation. Micro-cap biotech and ingredient names raise questions about liquidity, capital needs and listing status, so company news and filings are the main reference points.

Latest Company Context

Moolec describes itself as a science-based ingredient company developing products for food, pet food, animal feed and dietary supplements using molecular farming and precision fermentation. It is domiciled in the Cayman Islands. In 2026 the company announced several operational updates: a share consolidation took effect in early January; in late January a Nasdaq Hearings Panel granted continued listing subject to conditions; and in May 2026 the company said it had regained compliance with Nasdaq Capital Market requirements within the panel period. On the operating side, it reported completing the first phase of GLASO industrialisation in April, a molecular-farming breakthrough expressing bovine myoglobin in pea seeds, and the completion of its 2026 GLASO commercial planting campaign in the United States in May. 2024 revenue was $5.63 million, up from about $0.9 million in 2023, with a loss of $7.31 million.

Key Business Drivers

Commercial scale-up is central: the company's strategy rests on converting molecular-farming crops such as GLASO, which produces a GLA-rich oil, into revenue. Regulatory and customer acceptance of novel ingredients may influence timing. Second, balance sheet strength matters. The earlier stockholders' equity deficiency and the reverse split show the company has needed to manage listing requirements. Third, funding: small-cap ingredient developers often rely on equity or debt raises, which can dilute existing holders. Fourth, agricultural execution, including planting results and crushing yields, could affect cost and supply.

What Investors Should Watch

The next earnings date is estimated for October 23, 2026. Investors may watch whether the report explains Friday's decline and provides updated revenue, cash and equity figures. Other items include any Nasdaq correspondence regarding bid price or equity, announcements of financing, and commercial updates such as supply agreements for GLASO or myoglobin-related ingredients. Trading halts for volatility have been noted on the stock, so investors may also watch how liquidity behaves around news.

Operational Milestones Beside Listing and Capital Questions

Moolec's 2026 mixes operating milestones, including GLASO industrialisation and a molecular-farming breakthrough, with listing-requirement management. Its primary filings are the reference for the numbers.